Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?

European Journal of Nuclear Medicine

Volumn 27, Issue 10, 2000, Pages 1564-1578

  Kostakoglu, Lale ^a   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Fluorine 18 fluorodeoxyglucose; Hodgkin's disease; Lymphoma; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GALLIUM 67;

CANCER CHEMOTHERAPY; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; FOLLOW UP; GLYCOLYSIS; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RELIABILITY; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

FLUDEOXYGLUCOSE F 18; GALLIUM RADIOISOTOPES; HUMAN; LYMPHOMA; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033778133     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590000340     Document Type: Review

References (84)

1. Computed tomography of abdominal para-aortic lymph node disease: Preliminary observation with a 6 second scanner
2. Planning mantle radiation therapy in patients with Hodgkin's disease: The role of gallium-67 scintigraphy
3. A comparison of gallium-67 single photon emission computed tomography and computed tomography in mediastinal Hodgkin's disease
4. Accuracy of computed tomography in detecting intra-abdominal and pelvic adenopathy in lymphoma
5. Computed tomography, lymphography and staging laparotomy: Correlations in initial staging of Hodgkin's disease
6. Magnetic resonance imaging and Ga-67 scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study
7. A fluorinated glucose analog, 2-fluoro-2deoxy-D-glucose (F-18)
8. 18F] fluoro-2-deoxy-D-glucose: Correlation with CT
9. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
10. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
11. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
12. PET-FDG whole-body imaging in staging Hodgkin's disease: Comparison to conventional imaging
13. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma
14. Lymphoma: Role of whole body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging
15. Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment
16. 18F-FDG to detect residual disease after therapy for malignant lymphoma
17. Functional imaging of Hodgkin's disease with FDG-PET and gallium-67
18. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
19. 18F FDG PET in gastric non-Hodgkin's lymphoma
20. Extranodal malignant lymphoma: Detection with FDG PET versus CT
21. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
22. 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
23. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
24. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease
25. Normal lymph node size in the mediastinum: A retrospective study in two patient groups
26. Magnetic resonance imaging in diffuse malignant bone marrow diseases
27. Primary intracranial CNS lymphoma: MR manifestations
28. Bone marrow involvement in lymphoma: The importance of marrow magnetic resonance imaging
29. Magnetic resonance imaging of the bone marrow in lymphomas and leukemias
30. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging
31. Single-photon emission computed tomography gallium imaging versus computed tomography: Predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma
32. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy
33. 67Ga scintigraphy
34. 67Ga scintigraphy after one cycle of chemotherapy
35. Use of Ga-67 SPECT in patients with malignant lymphoma after primary chemotherapy for further treatment planning: Comparison with spiral CT
36. Validation of gallium-67 citrate single photon emission tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum
37. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease
38. Ga-67 scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma
39. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma
40. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma
41. Hodgkin's disease and non-Hodgkin's lymphoma
42. Computed tomography in the diagnosis, staging, and management of abdominal lymphoma
43. Computed tomography as an adjunct in the staging of Hodgkin's disease and non-Hodgkin's lymphomas
44. Proliferative activity and DNA index do not significantly predict survival in primary central nervous system lymphoma
45. Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms
46. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
47. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
48. Predicting malignancy grade with PET in non-Hodgkin's lymphoma
49. Comparison of fluorine-18 2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma
50. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in evaluation of lymphoma
51. Hodgkin's disease: Clinical and radiological prognostic factors in a laparotomy series
52. Prognostic factors for positive surgical staging in patients with Hodgkin's disease
53. Prognostic indicators of laparotomy findings in clinical stage III supradiaphragmatic Hodgkin's disease
54. Computed tomography of the abdomen and pelvis in non-Hodgkin lymphoma
55. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease
56. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver
57. FDG-PET in differentiating lymphoma from non-malignant central nervous system lesions in patients with AIDS
58. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET)
59. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation
60. Detection of lymphoma in bone marrow by whole-body positron emission tomography
61. 18-F-fluorodeoxyglucose-positron emision tomography as a new approach to detect lymphomatous bone marrow
62. Evaluation of FDG-PET in the detection of bone marrow involvement in lymphoma
63. Comparison of FDG-PET and Ga-67 SPECT in staging of lymphoma
64. 18F fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid-PET) for staging of lymphoma: Comparison with Ga-67 scintigraphy
65. Prognostic factors in aggressive malignant lymphomas. Description and validation of prognostic index that could identify patients requiring a more intensive therapy
66. Residual disease or fibrosis
67. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management
68. Clinical value of FDG PET for therapy monitoring of malignant lymphoma - Results of a retrospective study in 72 patients
69. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
70. Positron emission tomography with fluorodeoxyglucose after first line chemotherapy in non-Hodgkin's lymphoma
71. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy
72. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and gallium-67 scintigraphy in staging and follow-up of patients with lymphoma
73. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study
74. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial
75. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
76. Abdominal lymphadenopathy: Spectrum of CT findings
77. Upper abdominal lymph nodes: Criteria for normal size determined with CT
78. The number and size of normal mediastinal lymph nodes: A postmortem study
79. FDG-PET influences the clinical management of lymphoma patients
80. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type
81. Mediastinal large cell lymphoma: Prognostic significance of CT findings at presentation and after treatment
82. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma
83. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma
84. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease